ExchangeDEX+
Buy CryptoMarketsSpotFuturesGOLDEarnEvents
More
Partnership designates Made Scientific as exclusive cell therapy CDMO partner for Streamline Bio’s platform, accelerating development of autonomous manufacturingPartnership designates Made Scientific as exclusive cell therapy CDMO partner for Streamline Bio’s platform, accelerating development of autonomous manufacturing

Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program to Advance AI-Driven Robotic Automation for Cell Therapy Manufacturing

Author: AI Journal
Source: AI Journal
2026/02/11 00:46
3 min read
BIO Protocol
BIO$0.02497-5.05%
Cellframe
CELL$0.0628-5.42%
MASS
MASS$0.0002878-11.58%

Partnership designates Made Scientific as exclusive cell therapy CDMO partner for Streamline Bio’s platform, accelerating development of autonomous manufacturing workflows in GMP cleanroom environments

PRINCETON, N.J. and CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ — Made Scientific, a leading clinical- and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, Inc., a next-generation autonomous robotics company transforming biomanufacturing with AI-driven precision robotics, today announced the launch of an exclusive Early Adopter and Design Partner Program.

Through this program, Made Scientific will serve as Streamline Bio’s exclusive early adopter, design partner, and preferred CDMO partner for the co-development, integration, and validation of Streamline Bio’s AI-driven robotic manufacturing platform in a GMP-ready environment. Activities are designed to accelerate the development of automated workflows to include new unit operations, enhanced analytics/data capture, and other agentic AI-based improvements needed to support repeatable, scalable GMP operations. Studies will also evaluate autonomous rapid CAR-T manufacturing through end-to-end automation of critical process steps using industry-standard platforms, targeting cycle-time optimization, process robustness, and operational scalability.

“We are pleased to formalize our role as Streamline Bio’s exclusive CDMO technology partner as they work to redefine cell therapy manufacturing through advanced AI-driven automation,” said Syed T. Husain, Chairman & CEO of Made Scientific. “Integrating and validating Streamline Bio’s technology within our GMP manufacturing operations in Princeton, NJ allows us to advance this technology in a real-world GMP setting — reinforcing our commitment to delivering scalable, reproducible, and efficient manufacturing solutions for cell therapy developers.”

“Streamline Bio’s technology is purpose-built to deliver low-cost, versatile, and scalable automation for life science manufacturing,” said Rodney Rietze, Ph.D., President & CEO of Streamline Bio. “By partnering with Made Scientific as our exclusive early adopter CDMO, we are accelerating our cell and gene therapy product development roadmap and building toward a safe, compliant, and cost-effective manufacturing solution that supports the entire life science community.”

This expanded partnership builds upon the companies’ previously announced collaboration, further deepening their joint commitment to advancing scalable, automated manufacturing solutions with the potential to streamline operations, reduce cost of goods, and broaden patient access to transformative cell therapies.

About Made Scientific 
Made Scientific is a leading US-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical- and commercial-supply. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the agility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit www.madescientific.com.

About Streamline Bio 
Streamline Bio is a versatile, AI-driven, autonomous precision robotics company transforming how advanced therapies are manufactured. Whether supporting early-stage development or full-scale production, its modular robotic platform evolves with manufacturer needs – seamlessly integrating fluid handling, closed-loop automation, and scalable orchestration into existing workflows. For more information, visit www.streamlinebio.ai.

For media inquiries, please contact:
Made Scientific: media@madescientific.com 
Streamline Bio: info@streamlinebio.ai

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/made-scientific-and-streamline-bio-launch-exclusive-early-adopter-program-to-advance-ai-driven-robotic-automation-for-cell-therapy-manufacturing-302684018.html

SOURCE Made Scientific, Inc.

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0.02497
$0.02497$0.02497
-2.30%
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Fed Decides On Interest Rates Today—Here’s What To Watch For

Fed Decides On Interest Rates Today—Here’s What To Watch For

The post Fed Decides On Interest Rates Today—Here’s What To Watch For appeared on BitcoinEthereumNews.com. Topline The Federal Reserve on Wednesday will conclude a two-day policymaking meeting and release a decision on whether to lower interest rates—following months of pressure and criticism from President Donald Trump—and potentially signal whether additional cuts are on the way. President Donald Trump has urged the central bank to “CUT INTEREST RATES, NOW, AND BIGGER” than they might plan to. Getty Images Key Facts The central bank is poised to cut interest rates by at least a quarter-point, down from the 4.25% to 4.5% range where they have been held since December to between 4% and 4.25%, as Wall Street has placed 100% odds of a rate cut, according to CME’s FedWatch, with higher odds (94%) on a quarter-point cut than a half-point (6%) reduction. Fed governors Christopher Waller and Michelle Bowman, both Trump appointees, voted in July for a quarter-point reduction to rates, and they may dissent again in favor of a large cut alongside Stephen Miran, Trump’s Council of Economic Advisers’ chair, who was sworn in at the meeting’s start on Tuesday. It’s unclear whether other policymakers, including Kansas City Fed President Jeffrey Schmid and St. Louis Fed President Alberto Musalem, will favor larger cuts or opt for no reduction. Fed Chair Jerome Powell said in his Jackson Hole, Wyoming, address last month the central bank would likely consider a looser monetary policy, noting the “shifting balance of risks” on the U.S. economy “may warrant adjusting our policy stance.” David Mericle, an economist for Goldman Sachs, wrote in a note the “key question” for the Fed’s meeting is whether policymakers signal “this is likely the first in a series of consecutive cuts” as the central bank is anticipated to “acknowledge the softening in the labor market,” though they may not “nod to an October cut.” Mericle said he…
Share
BitcoinEthereumNews2025/09/18 00:23
Robinhood Chain Public Testnet Launch: A Strategic Pivot into Ethereum’s Layer 2 Ecosystem

Robinhood Chain Public Testnet Launch: A Strategic Pivot into Ethereum’s Layer 2 Ecosystem

BitcoinWorld Robinhood Chain Public Testnet Launch: A Strategic Pivot into Ethereum’s Layer 2 Ecosystem In a significant move that expands its footprint beyond
Share
bitcoinworld2026/02/11 10:05
Russian State Duma passes bill on cryptocurrency seizure and confiscation procedures

Russian State Duma passes bill on cryptocurrency seizure and confiscation procedures

PANews reported on February 11 that, according to Bits.media, the Russian State Duma has passed a procedural law on the seizure and confiscation of cryptocurrencies
Share
PANews2026/02/11 09:54